Archives
-
Calcein AM/PI Staining: Five Key Questions
2026-10-05
A source-grounded overview of what the Live-Dead Cell Staining Kit I measures, how to interpret Calcein AM/PI fluorescence, and where the assay’s evidence and applicability end—especially in biomaterials and osteoporotic bone-regeneration research.
-
Deracoxib: From COX-2 Biology to Translational Insight
2026-10-05
Deracoxib is more than a selective COX-2 inhibitor label: its translational value depends on connecting prostaglandin biology, nitric oxide signaling, apoptosis, cell context, and combination-treatment risk. Evidence from normal canine mammary epithelial cells offers a useful starting point while also showing why protection of healthy cells must not be confused with antitumor synergy.
-
Data-Driven Design of Small-Molecule Libraries
2026-10-04
Moret et al. developed a data-driven framework for comparing and designing focused small-molecule collections using target coverage, selectivity, phenotypic effects, chemical structure, development status, and user priorities. The study showed that optimized libraries can reduce redundancy while improving coverage of kinase and liganded-genome targets, providing a stronger basis for chemical biology research than informal compound selection alone.
-
BMS-345541 Hydrochloride: Research Context
2026-10-03
BMS-345541 hydrochloride is described by APExBIO as a selective IKK inhibitor, but the supplied primary study did not test this compound. Instead, Du and colleagues provide genetic and in vivo evidence that PPP1R3G–PP1γ regulates RIPK1-dependent apoptosis and necroptosis, offering context for conceptual NF-κB and cell-death research while leaving compound-specific claims unverified.
-
GPNMB Model Predicts Immunotherapy Response in ESCC
2026-10-02
This study identifies circulating soluble GPNMB as both a mechanistic driver and a predictive biomarker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors develop a multimodal model that connects tumor–immune biology with clinically practical response prediction.
-
MLN8237 (Alisertib) Assay Workflows
2026-10-01
MLN8237 (Alisertib) enables selective Aurora A perturbation across cell-cycle, apoptosis, and preclinical tumor studies. This workflow pairs its strong kinase selectivity with a flow-cytometric aneugen mechanism assay to distinguish mitotic kinase effects from tubulin-driven chromosome missegregation.
-
MMAE and Tumor Plasticity: A Translational Playbook
2026-10-01
Monomethyl auristatin E is more than a potent tubulin polymerization inhibitor: it is a strategic antibody-drug conjugate payload whose value depends on tumor state, delivery, assay design, and translational context. This article connects the EBV–LMP1–STAT5A–HDAC1/2 plasticity axis in nasopharyngeal carcinoma with a disciplined framework for evaluating MMAE in targeted cancer therapy.
-
Cisplatin: Reliable Assay Design & Selection
2026-09-30
Learn how Cisplatin (SKU A8321) can improve interpretation of viability, proliferation, and apoptosis experiments through disciplined formulation, handling, and endpoint selection. This scenario-based guide connects DNA crosslinking biology with practical strategies for cancer research and chemotherapy resistance studies.
-
DAPI Workflows for Nuclear and Apoptosis Assays
2026-09-30
DAPI Solution (1 mg/mL) supports high-contrast nuclear visualization in fixed cells, membrane-compromise screening, and flow cytometry DNA staining. This practical guide connects those readouts to PAD4–NET research while emphasizing controls, assay boundaries, and troubleshooting.
-
Prochlorperazine Trial for Acute Mountain Sickness
2026-09-29
This randomized, double-blind trial protocol evaluates whether prochlorperazine maleate can prevent acute mountain sickness during rapid ascent, extending its established antiemetic and migraine-related rationale into altitude medicine. The study’s controlled design, standardized ascent, placebo comparison, and Lake Louise outcome assessment provide a clear framework for determining whether a dopamine D2 receptor antagonist has clinically useful prophylactic activity.
-
Panobinostat (LBH589) Experimental Workflows
2026-09-29
Build reproducible Panobinostat workflows that distinguish HDAC target engagement, growth arrest, and apoptosis across cancer and stromal-cell models. A reference study in form-deprivation myopia also shows how LBH589 can connect macrophage polarization with extracellular-matrix remodeling, opening a practical route to mechanism-focused assays.
-
Viral RIPK3 Degradation and Inflammation
2026-09-28
Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that hijacks host SCF ubiquitin-ligase machinery to suppress necroptosis and reshape orthopoxvirus pathogenesis. The study links viral control of RIPK3 turnover with inflammation, replication, and mortality, while providing a framework for investigating regulated protein degradation in infection biology.
-
EX 527 (SEN0014196) for SIRT1 Studies
2026-09-28
EX 527 (SEN0014196) is a selective SIRT1 catalytic activity inhibitor used to investigate SIRT1-dependent biology, including p53 acetylation and cell survival. In aging-bone research, it can support tests of whether SIRT1 activity is necessary for observed vascular and osteogenic effects, but it does not reproduce SIRT1 activation.
-
Salinomycin Assay Design for HCC Research
2026-09-27
A practical, evidence-based guide to using Salinomycin (SKU A3785) in hepatocellular carcinoma research, from endpoint selection to stock handling and interpretation. It distinguishes viability from cell killing and summarizes product specifications without assuming an unreported dose or assay window.
-
Lactate–GPR81–FARP1 Controls Glucose Uptake
2026-09-26
The study identifies lactate as a signal that can promote skeletal-muscle glucose uptake independently of insulin, tracing the response through GPR81, FARP1, RAC1, and GLUT4 translocation. Its combination of genetic, pharmacological, and human-association evidence positions this pathway as a potential complement to insulin-mediated glucose control, while leaving important questions about clinical translation open.